Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takahiro Ebata

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Breast Cancer Research and Treatment|June 28, 2023
HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivityNobuaki Arai, Naoko Hattori, Satoshi Yamashita, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 18, 2017
The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian CarcinomaTakahiro Ebata, Mayu Yunokawa, Hiroshi Yoshida, et al.
Oncology|April 4, 2018
Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous TumorTakahiro Ebata, Tatsunori Shimoi, Seiko Bun, et al.
Cancer Chemotherapy and Pharmacology|August 15, 2016
Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancerSeiko Bun, Mayu Yunokawa, Takahiro Ebata, et al.
Cancer Chemotherapy and Pharmacology|November 4, 2020
Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignanciesShigehisa Kitano, Toshio Shimizu, Takafumi Koyama, et al.
Investigational New Drugs|May 25, 2019
Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumoursTakahiro Ebata, Toshio Shimizu, Yutaka Fujiwara, et al.
Molecules (Basel, Switzerland)|September 5, 2019
DMPK is a New Candidate Mediator of Tumor Suppressor p53-Dependent Cell DeathKatsuhiko Itoh, Takahiro Ebata, Hiroaki Hirata, et al.
Cancer Science|March 4, 2024
Clinical features and impact of p53 status on sporadic mismatch repair deficiency and Lynch syndrome in uterine cancerMayumi Kobayashi Kato, Erisa Fujii, Yuka Asami, et al.
Cancer Chemotherapy and Pharmacology|October 26, 2022
A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumorsShigehisa Kitano, Yutaka Fujiwara, Toshio Shimizu, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Breast Cancer Research and Treatment|June 28, 2023
HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivityNobuaki Arai, Naoko Hattori, Satoshi Yamashita, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 18, 2017
The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian CarcinomaTakahiro Ebata, Mayu Yunokawa, Hiroshi Yoshida, et al.
Oncology|April 4, 2018
Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous TumorTakahiro Ebata, Tatsunori Shimoi, Seiko Bun, et al.
Cancer Chemotherapy and Pharmacology|August 15, 2016
Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancerSeiko Bun, Mayu Yunokawa, Takahiro Ebata, et al.
Cancer Chemotherapy and Pharmacology|November 4, 2020
Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignanciesShigehisa Kitano, Toshio Shimizu, Takafumi Koyama, et al.
Investigational New Drugs|May 25, 2019
Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumoursTakahiro Ebata, Toshio Shimizu, Yutaka Fujiwara, et al.
Molecules (Basel, Switzerland)|September 5, 2019
DMPK is a New Candidate Mediator of Tumor Suppressor p53-Dependent Cell DeathKatsuhiko Itoh, Takahiro Ebata, Hiroaki Hirata, et al.
Cancer Science|March 4, 2024
Clinical features and impact of p53 status on sporadic mismatch repair deficiency and Lynch syndrome in uterine cancerMayumi Kobayashi Kato, Erisa Fujii, Yuka Asami, et al.
Cancer Chemotherapy and Pharmacology|October 26, 2022
A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumorsShigehisa Kitano, Yutaka Fujiwara, Toshio Shimizu, et al.
Pageof 3